论文部分内容阅读
人类母系表达基因3(MEG3)是目前研究最为广泛的长链非编码RNAs(lnc RNAs)之一,在肿瘤的发生发展和侵袭转移等过程中发挥着重要的作用。最近,大量研究结果表明MEG3在多种肿瘤的癌组织中的表达水平明显低于癌旁正常组织,在正常机体中发挥着抑癌基因的作用。也有研究者发现癌组织中MEG3处于低表达状态时提示着肿瘤可能发生转移。本研究目的是综合分析癌症病人中MEG3表达水平与肿瘤转移发生率间的关系,探讨MEG3是否可以作为判断患者发生肿瘤转移的潜在标志物。本次研究利用计算机检索维普数据库、万方数据库、中国知网(CNKI)数据库和Pub Med数据库,检索时间截止至2016年4月。收集符合标准的所有研究,利用Meta分析进行数据处理并探讨MEG3表达水平与患者肿瘤转移发生率间的关系。Meta分析共纳入5个研究,包括302例样本资料。结果表明:MEG3低表达组中的患者发生肿瘤转移人数较MEG3高表达组多。说明癌症病人中MEG3的表达水平与肿瘤转移发生率相关,MEG3低表达的患者发生肿瘤转移的概率明显高于MEG3高表达的患者。因此,MEG3可以作为预测癌症患者是否发生肿瘤转移的潜在生物标志物。
Human maternally expressed gene 3 (MEG3) is one of the most widely studied long-chain non-coding RNAs (lnc RNAs) and plays an important role in tumorigenesis, invasion and metastasis. Recently, a large number of studies have shown that MEG3 expression levels in many cancerous tissues were significantly lower than normal tissues, which play the role of tumor suppressor genes in normal tissues. Some researchers also found that MEG3 in cancer tissue is in a low expression state, suggesting that the tumor may have metastasis. The aim of this study is to analyze the relationship between the expression level of MEG3 and the incidence of tumor metastasis in cancer patients and to explore whether MEG3 can be used as a potential biomarker to determine the tumor metastasis in patients. This research uses computer to search VIP database, Wanfang database, CNKI database and Pub Med database. The search time is up to April 2016. All of the eligible studies were collected and analyzed using Meta-analysis for data processing and to investigate the relationship between MEG3 expression and the incidence of tumor metastases in patients. A total of 5 studies were included in the meta-analysis, including 302 sample data. The results showed that the number of tumor metastasis in MEG3 low expression group was higher than that in MEG3 high expression group. It shows that the expression level of MEG3 in cancer patients is related to the incidence of tumor metastasis. The probability of tumor metastasis in MEG3 low expression patients is obviously higher than that in MEG3 high expression patients. Therefore, MEG3 can be used as a potential biomarker for predicting tumor metastasis in cancer patients.